NEW YORK, March 29 – MiraiBio and BioSource International said Thursday they have agreed to jointly develop biological assays for use in drug discovery using Luminex’s LabMAP technology.

BioSource, based in Camarillo, Calif., will develop assay panels related to extracellular signaling, signal transduction, and cytokine research, while MiraiBio, formerly the Genetic Systems Division of Hitachi Software Engineering, will write software to accompany the assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.